Show simple item record

dc.contributor.authorÁlvarez, Beatriz
dc.contributor.authorNavarrete-Muñoz, María A
dc.contributor.authorBriz, Verónica 
dc.contributor.authorOlmedillas-López, Susana
dc.contributor.authorNistal, Sara
dc.contributor.authorCabello, Alfonso
dc.contributor.authorPrieto, Laura
dc.contributor.authorGórgolas, Miguel
dc.contributor.authorGarcía-Arranz, Mariano
dc.contributor.authorBenito, José M
dc.contributor.authorRallón, Norma
dc.date.accessioned2022-05-24T10:20:14Z
dc.date.available2022-05-24T10:20:14Z
dc.date.issued2022-03-24
dc.identifier.citationSci Rep. 2022 Mar 24;12(1):5095.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14483
dc.description.abstractThe role of HCV on the HIV reservoir is controversial since the reduction on HIV-DNA levels after HCV eradication with IFNα/RBV treatment seems to be the result of drugs instead of HCV clearance. We assessed whether HCV eradication can decrease HIV-DNA content in HIV/HCV-coinfected patients treated with direct-acting antivirals, DAAs (IFNα/RBV-free regimens). Cell-associated HIV-DNA was measured by ddPCR in 25 HIV-monoinfected and 25 HIV/HCV-coinfected patients. There were no differences in HIV-DNA levels between groups neither at baseline nor at 12 weeks after DAAs treatment completion. Our results indicate that HCV does not appear to influence the HIV reservoir size and suggest the lack of an anti-HIV action for DAAs.es_ES
dc.description.sponsorshipThis work was supported by projects PI14/00518, RD16/0025/0013 integrated into the State Plan for Scientific and Technical Research and Innovation from the General Sub-Directorate for research assessment and promotion, Spanish Carlos III Institute of Health (ISCIII) co-funded by the European Regional Development Fund (ERDF). Maria A Navarrete-Muñoz was funded by the Spanish Directorate General for Research and Technological of the “Comunidad de Madrid” [grant: IND2018/BMD9651]. Norma Rallón is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III [grant: CPII19/00025].es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleHIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapyes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35332180es_ES
dc.format.volume12es_ES
dc.format.number1es_ES
dc.format.page5095es_ES
dc.identifier.doi10.1038/s41598-022-08871-0es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderPlan Nacional de I+D+i (España)es_ES
dc.contributor.funderEuropean Regional Development Fund es_ES
dc.contributor.funderComunidad de Madrid es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-022-08871-0es_ES
dc.identifier.journalScientific Reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0013/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI14/00518es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CPII19/00025es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional